Eu­ro­pean reg­u­la­tors rec­om­mend re­jec­tion of Mer­ck’s Covid-19 drug mol­nupi­ravir

Eu­ro­pean reg­u­la­tors rec­om­mend­ed the EMA re­ject Mer­ck’s Covid an­tivi­ral, say­ing that there’s not enough ev­i­dence it works in pa­tients.

Mer­ck and part­ner Ridge­back Bio­ther­a­peu­tics an­nounced the CHMP’s de­ci­sion on Fri­day.

The com­mit­tee re­fused to rec­om­mend the ap­proval of Lagevrio, al­so known as mol­nupi­ravir, by ini­tial­ly stat­ing that the re­view has been on­go­ing for more than a year. The com­mit­tee had sup­port­ed de­ci­sions from mem­ber states start­ing in No­vem­ber 2021, if they want­ed to con­sid­er ear­ly use of mol­nupi­ravir be­fore any po­ten­tial ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER